Zhejiang Aoxiang Pharmaceutical Co., Ltd. was founded in April 2010 and listed on the Shanghai Stock Exchange on May 9, 2017 with the stock code of 603229.

The company is located in the Taizhou Bay Economic and Technological Development Zone and is a national high-tech enterprise. At present, the company has established national postdoctoral workstations, platforms such as Zhejiang Key Enterprise Research Institute, Provincial Enterprise Technology Center, and Provincial R&D Center. There are currently over 1000 employees and a research, development, and analysis team consisting of over 300 people, including doctoral and master's degrees.

The company is mainly engaged in the research and development, production, and sales of pharmaceutical preparations, characteristic raw materials, and key pharmaceutical intermediates, as well as providing customized processing and research and development services for customers; The products are mainly exported to countries and regions such as Europe, the United States, Japan, and South Korea. In 2022, the company's operating revenue increased by 34.2% year-on-year, and its net profit increased by 61.29% year-on-year.

The company's products are mainly divided into eight categories: liver disease, respiratory system, cardiovascular and cerebrovascular products, high-end fluoride products, Prostaglandin, antibacterial, gout, and anti-tumor products. The products developed have many chiral structures, high research and development difficulties, high technical barriers, and unique production processes. The company attaches great importance to technological innovation and research and development. In the past three years, R&D investment accounted for more than 10% of operating revenue.

We are specialized in effectively transferring R&D and lab-processes into industrial production workshop within the promised timeline and achieving the expected quality.

We provide products to all medicinal health indications; currently serving  customers with medical products for liver disease, respiratory systems, cardiac and cerebral vessels, and CNS indications. Special product categories are high-end fluorine products, prostaglandins, antimicrobial and oncology products. For customers we provide process development and manufacturing services.

Our goal is to develop into an integrated one-stopshop for Pharmaceutical companies, providing development and manufacturing services for Pharmaceutical intermediates, APIs and Drug Products, support the Pharma companies in the generation of new medicines, and serving human health and provide products to patients in need. It is our objective to provide customers with the best chemical processes for their pharmaceutical products and create value for our customers.

We are driven by our values of transparency, integrity and openness to win the trust of our customers in order todevelop long-lasting relationships and achieve win-win results for all parties involved.